Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: A noncomparative phase II study

Anti-Cancer Drugs

Volumn 19, Issue 3, 2008, Pages 303-307

  Park, Se Hoon ^a   Kim, Young Saing ^a   Hong, Junshik ^a   Park, Jinny ^a   Nam, Eunmi ^a   Cho, Eun Kyung ^a   Shin, Dong Bok ^a,b   Lee, Jae Hoon ^a   Lee, Woon Kee ^b   Chung, Min ^b  

^a Department of Internal Medicine   (South Korea)

^b Gachon University College of Medicine   (South Korea)

Author keywords

Mitomycin C; S 1; Second line therapy; Stomach cancer

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; PACLITAXEL; ANTINEOPLASTIC AGENT; MITOMYCIN; OXONIC ACID; S 1 (COMBINATION); TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEMOLYTIC ANEMIA; HUMAN; LIVER TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN TOXICITY; STATISTICAL ANALYSIS; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; CHEMICALLY INDUCED DISORDER; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG COMBINATION; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; STOMACH TUMOR; SURVIVAL RATE;

ADULT; AGED; ANEMIA, HEMOLYTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FATIGUE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM METASTASIS; OXONIC ACID; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME;

EID: 45549091227     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3282f46ad8     Document Type: Article

References (29)

1. Bae JM, Won YJ, Jung KW, Park JG. Annual report of the Korean central cancer registry program 2000. Cancer Res Treat 2002; 34:77-83.
2. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71:587-591.
3. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8:163-168.
4. Van Cutsem E, Haller D, Ohtsu A. The role of chemotherapy in the current treatment of gastric cancer. Gastric Cancer 2002; 5 (Suppl 1):17-22.
5. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000; 58:191-197.
6. Maehara Y. S-1 in gastric cancer: a comprehensive review. Gastric Cancer 2003; 6 (Suppl 1):2-8.
7. Takahashi I, Kakeji Y, Emi Y, Sakurai M, Yonemura Y, Kimura Y, et al. S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects. Gastric Cancer 2003; 6 (Suppl 1):28-33.
8. Moertel CG. Clinical management of advanced gastrointestinal cancer. Cancer 1975; 36:675-682.
9. Baguley BC, Calveley SB, Crowe KK, Fray LM, O'Rourke SA, Smith GP. Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on colon 38 tumours in mice. Eur J Cancer Clin Oncol 1989; 25:263-269.
10. Russello O, Romanini A, Civalleri D, Rosso R, Nicolin A, Sobrero A. Time-dependent interactions between 5-fluorouracil and mitomycin C on a human colon carcinoma cell line, HCT-8, in vitro. Eur J Cancer Clin Oncol 1989; 25:571-572.
11. Preusser P, Achterrath W, Wilke H, Lenaz L, Fink U, Heinicke A, et al. Chemotherapy of gastric cancer. Cancer Treat Rev 1988; 15:257-277.
12. Ross P, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, et al. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 1997; 8:995-1001.
13. Tebbutt NC, Norman A, Cunningham D, Iveson T, Seymour M, Hickish T, et al. A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann Oncol 2002; 13:1568-1575.
14. Chong G, Cunningham D. What is the role of mitomycin C in advanced gastric cancer? Onkologie 2005; 28:125-126.
15. Verweij J, van der Burg ME, Pinedo HM. Mitomycin C-induced hemolytic uremic syndrome. Six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drug. Radiother Oncol 1987; 8:33-41.
16. Maisey N, Chau I, Cunningham D, Norman A, Seymour M, Hickish T, et al. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 2002; 20:3130-3136.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
18. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38:143-151.
19. Kinoshita K, Yonemura Y, Sawa T, Miyata T, Sakuma H, Matsuki N, et al. 5-Fluorouracil, methotrexate, leucovorin, CDDP and epirubicin (FEPMTX): a wide-spectrum regimen of salvage chemotherapy for high-grade advanced gastric cancer. Hepatogastroenterology 2003; 50:1716-1719.
20. Park SH, Kang WK, Lee HR, Park J, Lee KE, Lee SH, et al. Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen. Am J Clin Oncol 2004; 27:477-480.
21. Ohtsu A, Yoshida S, Saito D, Shimada Y, Miyamoto K, Fujii T, et al. An early phase II study of 5-fluorouracil combined with cisplatinum as a second line chemotherapy against metastatic gastric cancer. Jpn J Clin Oncol 1991; 21:120-124.
22. Giuliani F, Gebbia V, De Vita F, Maiello E, Di Bisceglie M, Catalano G, et al. Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (GOIM). Anticancer Res 2003; 23:4219-4222.
23. Schmitz SH, Voliotis DL, Schimke J, Diehl V. Continuous 5-fluorouracil and leucovorin as a second-line therapy for advanced gastric carcinoma. Oncology 1994; 51:502-506.
24. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-115.
25. Park SH, Lee WK, Chung M, Bang SM, Cho EK, Lee JH, et al. Quality of life in patients with advanced gastric cancer treated with second-line chemotherapy. Cancer Chemother Pharmacol 2006; 57:289-294.
26. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003; 21:54-59.
27. Koizumi W, Fukuyama Y, Fukuda T, Akiya T, Hasegawa K, Kojima Y, et al. Randomized phase II study comparing mitomycin, cisplatin plus doxifluridine with cisplatin plus doxifluridine in advanced unresectable gastric cancer. Anticancer Res 2004; 24:2465-2470.
28. Chollet P, Schoffski P, Weigang-Kohler K, Schellens JH, Cure H, Pavlidis N, et al. Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer 2003; 39:1264-1270.
29. Wilson D, Hiller L, Geh JI. Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol) 2005; 17:81-90.